| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis (NCT07683806) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-08-24 |
| A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer (NCT07621159) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-07-15 |
| HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma (NCT07697339) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-07-10 |
| A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants (NCT07559240) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-05-15 |
| A Study of HDM2024 in Participants With Advanced Solid Tumors (NCT07539285) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-04-10 |
| Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin (NCT07502001) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-04-08 |
| A Study of HDM2020 in Patients With Advanced Sq-NSCLC (NCT07638891) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-04-01 |
| Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes (NCT07521631) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-03-31 |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (NCT07417306) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-03-27 |
| Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma (NCT07529782) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-03-17 |
| A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects (NCT07594847) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-03-07 |
| A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT07394114) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2026-02-24 |
| A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (NCT07357831) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-12-26 |
| Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease (NCT07116928) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-11-30 |
| A Phase 1 Study of HDM2017 in Advanced Solid Tumors (NCT07274085) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-11-18 |
| Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes (NCT07279194) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-10-14 |
| A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin (NCT07331389) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-09-24 |
| Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (NCT07193459) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-08-12 |
| A Study of HDM2020 in Patients With Advanced Solid Tumors (NCT07098052) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-08-11 |
| A Study of HDM2012 in Patients With Advanced Solid Tumor (NCT07100249) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-08-06 |
| A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma (NCT07124936) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-07-30 |
| A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (NCT07082114) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-07-14 |
| A Study of HDM2005 in Patients With Advanced Solid Tumor (NCT07004296) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-05-29 |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin (NCT07109700) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-04-30 |
| Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (NCT07244003) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-03-29 |
| Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults (NCT06885021) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-03-28 |
| A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement (NCT06985615) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-03-18 |
| Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus (NCT06886126) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-02-07 |
| Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients (NCT07036172) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-01-03 |
| A Study of HDM2006 in Patients With Advanced Solid Tumor (NCT07377591) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-12-31 |
| Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis (NCT06631170) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-11-21 |
| Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study (NCT06648772) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-11-14 |
| A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects (NCT06608329) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-10-01 |
| A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. (NCT06601517) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-10-01 |
| Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. (NCT06634927) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-09-22 |
| A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects (NCT06576401) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-08-27 |
| A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects (NCT06562088) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-08-16 |
| A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor (NCT06615193) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-08-12 |
| HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects (NCT06520540) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-07-28 |
| Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults (NCT06500299) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-07-15 |
| To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (NCT06481085) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-06-27 |
| Phase Ib Clinical Study of HDM1005 Injection (NCT06637020) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-06-20 |
| Phase Ia Clinical Study of HDM1005 Injection (NCT06640647) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-03-19 |
| Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes (NCT06739044) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2023-09-20 |
| A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants (NCT05943977) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2023-03-02 |
| A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer (NCT05622890) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2022-08-18 |